体检人群非酒精性脂肪性肝病检出率及其危险因素分析*

doi:10.3969/j.issn.1672-5069.2023.01.010

Abstract

Abstract: Objective The aim of this study was to analyze the risk factors of non-alcoholic fatty liver diseases (NAFLD) in physical examination individuals. Methods 1742 persons received physical examination in our hospital between January 2018 and January 2020, and 485 individuals were eligible for this study based on inclusion and exclusion criteria. The NAFLD was found by ultrasonography in 78 cases and not in 407 cases. The visceral adipose tissue (VAT)was obtained by CT scan, and fasting plasma glucose (FPG) and other common blood parameters were assayed. The risk factors for NAFLD was analyzed by univariate and multivariate Logistic regression. Results The incidences of concomitant blood hypertension, diabetes and hyperlipidemia in patients with NAFLD were 29.5%, 35.9% and 51.3%, much higher than 18.7%, 23.8% and 23.6% (P<0.05), the body mass index, waist and hip circumference were (25.1±1.)kg/m², (90.4±6.3)cm and (101.3±8.4)cm, much higher than [(22.4±1.1)kg/m², (81.6±5.7)cm and (95.7±6.2)cm, respectively, P<0.05] in persons without NAFLD; serum TG, LDL-C and VAT were (2.9±0.3)mmol/L,(3.7±0.4)mmol/L and (146.3±12.1)cm², significantly higher than [(1.6±0.2)mmol/L, (3.1±0.2)mmol/L and (70.5±4.6)cm², respectively, P<0.05] in persons without NAFLD; serum ALT, FPG and UA levels were (56.6±11.7)u/L, (5.8±0.7)mmol/L and (387.8±36.3)μmol/L, all significantly higher than [(32.4±3.1)u/L, (5.1±0.4)mmol/L and (313.6±51.4)μmol/L, respectively, P<0.05] in persons without NAFLD; the multivariate Logistic regression analysis showed that the increased BMI, elevated VAT, concomitant blood hypertension, and elevated serum TG, LDL-C, ALT and UA levels were all the independent risk factors, while the increased serum HDL-C level was the protective factor for the existence of NAFLD. Conclusion The prevalence of NAFLD in physical examination individuals is relative high, and some increased body health, blood and imaging parameters hints its existence, and warrants further check-up.

Key words: Non-alcoholic fatty liver diseases, Visceral adipose tissue, Risk factors, Logistic analysis, Physical examination

Xu Weiqiang, Liu Shuping, Li Xiaomeng. Risk factors of non-alcoholic fatty liver diseases in physical examination individuals[J]. Journal of Practical Hepatology, 2023, 26(1): 35-38.

References

[1] Taheri H, Malek M, Ismail-Beigi F,et al. Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther, 2020,37(11):4697-4708.
[2] D'Abbondanza M, Ministrini S, Pucci G,et al. Very low-carbohydrate ketogenic diet for the treatment of severe obesity and associated non-alcoholic fatty liver disease: The role of sex differences. Nutrients, 2020,12(9):2748.
[3] 柴颖,郭宁,么焕新,等. 幽门螺杆菌根除治疗对非酒精性脂肪性肝病脂代谢及胰岛素抵抗的影响. 中华医院感染学杂志,2021,31(9):1319-1323.
[4] Esmail VAW, Mohammed MO, Al-Nimer MSM. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab J Gastroenterol, 2021,22(1):1-5.
[5] Craven L, Rahman A, Nair Parvathy S,et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial. Am J Gastroenterol, 2020,115(7):1055-1065.
[6] Herath HMM, Kodikara I, Weerarathna TP,et al. Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in Sri Lankan patients with type 2 diabetes: A single center study. Diabetes Metab Syndr, 2019,13(1):246-250.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186.
[8] Newsome PN, Buchholtz K, Cusi K,et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med, 2021,384(12):1113-1124.
[9] 柴颖,郭宁,么焕新,等. 幽门螺杆菌根除治疗对非酒精性脂肪性肝病脂代谢及胰岛素抵抗的影响. 中华医院感染学杂志,2021,31(9):1319-1323.
[10] Smith GI, Shankaran M, Yoshino M,et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest, 2020,130(3):1453-1460.
[11] Newsome PN, Sasso M, Deeks JJ,et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol, 2020,5(4):362-373.
[12] Kuchay MS, Krishan S, Mishra SK,et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia, 2020,63(11):2434-2445.
[13] Chen Y, Feng R, Yang X,et al. Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial. Am J Clin Nutr, 2019,109(6):1611-1619.
[14] Aso Y, Kato K, Sakurai S,et al. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract, 2019,73(5):e13335.
[15] Schübel R, Nonnenmacher T, Sookthai D, et al. Similar weight loss induces greater improvements in insulin sensitivity and liver function among individuals with NAFLD compared to individuals without NAFLD. Nutrients, 2019,11(3):544.
[16] Babu AF, Csader S, Männistö V,et al. Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool. Sci Rep, 2022,12(1):6485.
[17] 古丽斯亚·海力力,姚华,王淑霞,等. 乌鲁木齐市某区全民体检人群代谢综合征组分聚集性与非酒精性脂肪肝关系. 中华疾病控制杂志,2019,23(11):1358-1363.
[18] Loomba R, Noureddin M, Kowdley KV,et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology, 2021,73(2):625-643.
[19] Stahlschmidt FL, Tafarel JR, Menini-Stahlschmidt CM,et al. Hepatorenal index for grading liver steatosis with concomitant fibrosis. PLoS One, 2021,16(2):e0246837.
[20] Goodarzi R, Jafarirad S, Mohammadtaghvaei N,et al. The effect of pomegranate extract on anthropometric indices, serum lipids, glycemic indicators, and blood pressure in patients with nonalcoholic fatty liver disease: A randomized double-blind clinical trial. Phytother Res, 2021,35(10):5871-5882.

Risk factors of non-alcoholic fatty liver diseases in physical examination individuals

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Huang Danxia, Zhao Zhihui, Xiao Yuexing, et al. Berberine improves liver injuries and intestinal flora disorders in high-fat diet-induced non-alcoholic fatty liver disease in rats [J]. Journal of Practical Hepatology, 2023, 26(1): 23-26.
[2]	Wu Chengyong, Chen Chong, Liu Wenyan, et al. Prevalence of bacterial infection in patients with HBV-related acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2023, 26(1): 59-62.
[3]	Cai Yong, Li Jing, Ou Qin. Implications of serum omentin, retinol-binding protein-4 and propeptide of type I procollagen in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 800-803.
[4]	Fan Ye, Zhang Ximei, Zhang Yan. Clinical implication of serum cystatin C, lipoprotein α and nesfatin-1 levels in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 816-819.
[5]	Li Rong, Cao Jingjing, Li Jing, et al.. Triggering and impacting factors of prognosis in patients with hepatitis B virus-associated acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2022, 25(6): 832-835.
[6]	Shen Yiliang, Shen Dongyuan, Chen Yongying, et al.. Qualitative evaluation of intrahepatic nodules in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(6): 836-839.
[7]	Zheng Xiyan, Du Fei, Lin Zhiqun, et al.. Metabolic syndrome-related risk factor for disease progression of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(6): 877-880.
[8]	Zeng Ting, Lei Xiangyang, Bai Xiaosu. Protective effect of oxymatrine on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 624-627.
[9]	Nian Fulin, Lu Xiaolan. Non-alcoholic fatty liver disease and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(3): 314-317.
[10]	Wang Shisong, Lin Huixiong, Zhang Taisheng, et al. Short-term observation of metformin and dapagliflozin combination therapy in the treatment of patients with T2DM and NAFLD and their impact on serum dipeptidyl peptidase 4 and C-peptide levels [J]. Journal of Practical Hepatology, 2022, 25(3): 379-382.
[11]	Sun Yanan, Zeng Qinghuan, Liu Yuanzhi, et al. Influencing factors for prognosis of patients with acute-on-chronic liver failure and moderate or severe esophageal varices [J]. Journal of Practical Hepatology, 2022, 25(3): 391-394.
[12]	Qu Ying, Cai Xiaobo, Zhang Qidi, et al. Prevalence of serum anti-mitochondrial antibody-M2 antibody in health check-up individuals [J]. Journal of Practical Hepatology, 2022, 25(2): 203-206.
[13]	Liang Yebei, Yang Chunguang, Wang Kunfeng, et al. Epidemiologic investigation of non-alcoholic fatty liver diseases in whole adults of Blang ethnicity in Yunnan province [J]. Journal of Practical Hepatology, 2022, 25(2): 223-226.
[14]	Mo Chaoyan, Yang Youqiang, Zhong Yuan, et al. Implication of serum resistin and retinol-binding protein 4 in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2022, 25(2): 231-234.
[15]	Huang Die, Tian Haoyu, Li Yiling. Serum markers in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 297-300.